Failure of α-Galactosylceramide to prevent diabetes in virus-inducible models ot type 1 diabetes in the rat

In Vivo

Volumn 23, Issue 2, 2009, Pages 195-202

  Chopra, Prerna ^a   Diirio, Philip ^a   Pino, Steven C ^a   Wilson, S Brian ^b   Phillips, Nancy E ^a   Mordes, John P ^a   Rossini, Aldo A ^a   Greiner, Dale L ^a   Shultz, Leonardo D ^c   Bortell, Rita ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

BB rat; iNKT cells; NOD mouse; Type 1 diabetes; Galactosylceramide

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOBREEDING RAT; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE COMPARISON; DRUG TREATMENT FAILURE; EXPERIMENTAL DIABETES MELLITUS; FISCHER 344 RAT; GLYCEMIC CONTROL; IMMUNE RESPONSE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LATENT RAT PARVOVIRUS; LEWIS RAT; MOUSE; NATURAL KILLER T CELL; NONHUMAN; RAT; SPLEEN CELL; STRAIN DIFFERENCE; VIRUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GALACTOSYLCERAMIDES; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-4; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; RATS; SEX FACTORS; SPLEEN;

EID: 64549103393     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Godfrey DI and Kronenberg M: Going both ways: immune regulation via CDld-dependent NKT cells. J Clin Invest 114: 1379-1388, 2004.
2. Kronenberg M: Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900, 2005.
3. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L and Bendelac A: The mouse CD1d-restricted repertoire is dominated by a few autoreactive T-cell receptor families. J Exp Med 193: 893-904, 2001.
4. Van Kaer L and Joyce S: Innate immunity: NKT cells in the spotlight. Curr Biol 15: R429-R431, 2005.
5. Bendelac A, Savage PB and Teyton L: The biology of NKT cells. Annu Rev Immunol 25: 297-336, 2007.
6. Brossay L, Jullien D, Cardell S, Sydora BC, Burdin N, Modlin RL and Kronenberg M: Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol 159: 1216-1224, 1997.
7. Roark JH, Park SH, Jayawardena J, Kavita U, Shannon M and Bendelac A: CD1.1 expression by mouse antigen-presenting cells and marginal zone B-cells. J Immunol 160: 3121-3127, 1998.
8. Tsuji M: Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol Life Sci 63: 1889-1898, 2006.
9. Yamamura T, Miyamoto K, Illes Z, Pal E, Araki M and Miyake S: NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr Top Med Chem 4: 561-567, 2004.
10. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P and Kronenberg M: CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T-cells is highly conserved through mammalian evolution. J Exp Med 188: 1521-1528, 1998.
11. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K et al: CD1d-restricted and TCR-mediated activation of vαt14 NKT cells by glycosylceramides. Science 278: 1626-1629, 1997.
12. Cardell SL: The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice. Clin Exp Immunol 143: 194-202, 2006.
13. Linsen L, Somers V and Stinissen P: Immunoregulation of auto-immunity by natural killer T-cells. Hum Immunol 66: 1193-1202, 2005.
14. Seino K, Fujii S, Harada M, Motohashi S, Nakayama T, Fujisawa T and Taniguchi M: Vα14 NKT cell-mediated anti-tumor responses and their clinical application. Springer Semin Immunopathol 27: 65-74, 2005.
15. Anderson MS and Bluestone JA: The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23: 447-485, 2005.
16. Chen YG, Choisy-Rossi CM, Holl TM, Chapman HD, Besra GS, Porcelli SA et al: Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 174: 1196-1204, 2005.
17. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA et al: A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23: 115-126, 2005.
18. Wicker LS, Clark J, Fraser HI, Garner VE, Gonzalez-Munoz A, Healy B et al: Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun 25 Suppl: 29-33, 2005.
19. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV et al: The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7: 1052-1056, 2001.
20. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y et al: Activation of CD1d-restricted T-cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA 98: 13838-13843, 2001.
21. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV et al: Activation of natural killer T-cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 7: 1057-1062, 2001.
22. Mordes JP, Greiner DL and Rossini AA: Animal models of autoimmune diabetes mellitus. In: Diabetes Mellitus. A Fundamental and Clinical Text. LeRoith D, Taylor SI and Olefsky JM eds). Philadelphia, Lippincott Williams and Wilkins, pp. 430-441, 2000.
23. Mordes JP, Bortell R, Groen H, Guberski DL, Rossini AA and Greiner DL: Autoimmune diabetes mellitus in the BB rat. In: Animal Models of Diabetes: A Primer, Vol. 2. Sima AAF and Shafrir E (eds.). Amsterdam, Harwood Academic Publishers, pp 1-41, 2001.
24. Mordes JP, Guberski DL, Leif JH, Woda BA, Flanagan JF, Greiner DL et al: LEW.1WR1 rats develop autoimmune diabetes spontaneously and in response to environmental perturbation. Diabetes 54: 2727-2733, 2005.
25. Bortell R, Pino SC, Greiner DL, Zipris D and Rossini AA: The circle between the bedside and the bench: Toll-like receptors in models of viral induced diabetes. Ann NY Acad Sci 1150: 112-122, 2008.
26. + T-cell populations. J Immunol 170: 3592-3602, 2003.
27. Zipris D, Lien E, Xie JX, Greiner DL, Mordes JP and Rossini AA: TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol 174: 131-142, 2005.
28. Iwakoshi N, Greiner DL, Rossini AA and Mordes JP: Diabetes prone BB rats are severely deficient in natural killer T-cells. Autoimmunity 31: 1-14, 1999.
29. Matsuura A, Kinebuchi M, Chen HZ, Katabami S, Shimizu T, Hashimoto Y et al: NKT cells in the rat: Organ-specific distribution of NK T cells expressing distinct Vct14 chains. J Immunol 164: 3140-3148, 2000.
30. Porcelli SA and Modlin RL: The CD1 system: Antigen-presenting molecules for T-cell recognition of lipids and glycolipids. Annu Rev Immunol 17: 297-329, 1999.
31. Eberl G and MacDonald HR: Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Imraunol 30: 985-992, 2000.
32. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y et al: The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189: 1121-1128, 1999.
33. +NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 163: 93-101, 1999.
34. Gumperz JE, Miyake S, Yamamura T and Brenner MB: Functionally distinct subsets of CD1d-resticted natural killer T-cells revealed by CD1d tetramer staining. J Exp Med 195: 625-636, 2002.
35. Kent SC, Chen Y, Clemmings SM, Viglietta V, Kenyon NS, Ricordi C et al: Loss of IL-4 secretion from human type la diabetic pancreatic draining lymph node NKT cells. J Immunol 175: 4458-4464, 2005.
36. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M et al: Extreme Thl bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391: 177-181, 1998.
37. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A: Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110: 793-800, 2002.
38. Redondo MJ, Gottlieb PA, Motheral T, Mulgrew C, Rewers M, Babu S et al: Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes 48: 2166-2170, 1999.